Using a patient-based methodology, Datamonitor estimates that sales of multiple sclerosis drugs across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) total $8.6bn in 2011. With more efficacious and convenient product launches from a dynamic pipeline this market is expected to expand to $10.1bn in 2020, growing with a compound annual growth rate (CAGR) of 1.7%.
Features and benefits
- Access Datamonitor’s patient-based multiple sclerosis market forecast, with transparent methodologies and assumptions across the seven major markets.
- Evaluate sales value and volume forecasts to 2020 at the country, class, product, and indication level for disease modifying and symptomatic therapies
- Understand how market drivers and resistors will shape the future market dynamics.
- Quantify the impact of new products launches by understanding Datamonitor’s assumptions on launch dates, pricing, and penetration rates.
The seven major multiple sclerosis markets is expected to show slight value growth from 2011 to 2020 at a CAGR of 1.7% to generate $10.1 billion at the end of this period. This growth will be driven by drugs offering improved efficacy and a less invasive method of administration than current treatments.
By 2020, the US will remain the biggest marketplace for multiple sclerosis drug developers at $7.0bn. The UK is set to remain the smallest of the US and European markets and is forecast to reach $201m by 2020. High hurdles, such as NICE, have restricted market access and availability in the UK.
With a convenient mode of administration and improved efficacy, sales of Novartis’s Gilenya and Biogen’s BG-12 are expected to overtake older brands and become the highest-selling multiple sclerosis drugs with seven major market sales of $2.2bn and $1.2bn, respectively, in 2020.
Your key questions answered
- What degree of commercial success does Datamonitor forecast for key pipeline drugs such as BG-12, Aubagio, and Lemtrada?
- How will multiple sclerosis biosimilars impact the market?
- Will Avonex, Betaseron, Rebif, Copaxone and Tysabri retain market share upon increased competition?
- Will the UK market grow in the face of restrictive drug availability?